Milrinone Lactate

Inquiry

Cat Number

API0232009

CAS Number

100286-97-3

For research use only. We do not supply to patients.

For pharmaceutical-grade products or other inquiries, please contact our experts.

Product Detail Description Scientific Support Customer Q&A

CAS Number

100286-97-3

Storage

Store at room temperature

Synonyms

Milrinone Lactate In Dextrose; Milrinonelactate; DTXSID40881375

Molecular Formula

C15H15N3O4

Molecular Weight

301.3

Smiles

CC1=C(C=C(C(=O)N1)C#N)C2=CC=NC=C2.CC(C(=O)O)O

Appearance

White to off-white crystalline powder

Melting Point

>120°C (dec.)

General Description

Milrinone lactate is the lactate salt of milrinone, a synthetic bipyridine derivative that functions as a positive inotrope and vasodilator. Its chemical structure is 1,6-dihydro-2-methyl-6-oxo-[3,4'-bipyridine]-5-carbonitrile lactate. It is a white to off-white crystalline powder that is soluble in water.

Mechanism of Action

Milrinone acts as a selective inhibitor of phosphodiesterase type 3 (PDE3), an enzyme responsible for the breakdown of cyclic AMP (cAMP) in cardiac and vascular smooth muscle. This inhibition increases cAMP levels, leading to enhanced myocardial contractility (positive inotropy) and relaxation of vascular smooth muscle (vasodilation), which reduces afterload and improves cardiac output.

Application

Milrinone is indicated for the short-term management of congestive heart failure in patients who have not responded to standard therapy. It is used to improve hemodynamic parameters in patients with low cardiac output, often in the intensive care unit setting.

The MIDAS trial protocol describes a multicenter, double‑masked, placebo‑controlled RCT (n=316) testing prophylactic milrinone versus placebo to prevent post‑ligation cardiac syndrome (PLCS) or death within 7 days of patent ductus arteriosus closure in extremely premature infants. The primary outcome is a composite of PLCS or death. This will provide evidence on a treatment for a common, morbid complication.

Fig. 1 MIDAS trial patient journey timeline. (McNamara PJ, et al., 2025)

References

McNamara PJ, et al. Evaluating the efficacy and safety of milrinone for prevention of post-patent ductus arteriosus closure syndrome (the MIDAS trial) in extremely preterm infants: a multicentre, double-masked, randomised, placebo-controlled trial. BMJ Open. 2025;15(8):e105018.

Does Milrinone Lactate require protection from light and moisture during storage?

Yes, it is sensitive to both light and moisture. Light causes photodegradation and moisture promotes hydrolysis of the lactate ester. Store in light-resistant, tightly sealed containers with desiccant.

What is the recommended storage temperature for Milrinone Lactate?

Store at controlled room temperature (15–25°C). Avoid excessive heat above 30°C, which accelerates degradation.

Is Milrinone Lactate stable in injectable solution formulations?

Aqueous solutions are stable when protected from light and stored at room temperature.

How is the impurity milrinone (free base, a hydrolysis product) monitored?

This primary degradation product is specifically quantified using a stability-indicating HPLC method, ensuring it remains within pharmacopoeial limits.